Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Duligotuzumab |
| Trade Name | |
| Synonyms | MEHD7945A |
| Drug Descriptions |
Duligotuzumab (MEHD7945A) is a two-in-one antibody that inhibits both ERBB3 (HER3) and EGFR signaling, resulting in greater efficacy than monospecific HER antibodies against multiple tumor models (PMID: 22014573, PMID: 29506988). |
| DrugClasses | EGFR Antibody 72 HER3 (ERBB3) Antibody 28 |
| CAS Registry Number | 1312797-14-0 |
| NCIT ID | C116628 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Afatinib + Duligotuzumab | Afatinib Duligotuzumab | 0 | 0 |
| Cobimetinib + Duligotuzumab | Cobimetinib Duligotuzumab | 0 | 1 |
| Duligotuzumab | Duligotuzumab | 0 | 2 |
| Duligotuzumab + Radiotherapy | Duligotuzumab Radiotherapy | 0 | 0 |